1
|
Ouyang W, Kilner KJ, Xavier RMP, Liu Y, Lu Y, Feller SM, Pitts KM, Wu M, Ausra J, Jones I, Wu Y, Luan H, Trueb J, Higbee-Dempsey EM, Stepien I, Ghoreishi-Haack N, Haney CR, Li H, Kozorovitskiy Y, Heshmati M, Banks AR, Golden SA, Good CH, Rogers JA. An implantable device for wireless monitoring of diverse physio-behavioral characteristics in freely behaving small animals and interacting groups. Neuron 2024; 112:1764-1777.e5. [PMID: 38537641 PMCID: PMC11256974 DOI: 10.1016/j.neuron.2024.02.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 02/08/2024] [Accepted: 02/28/2024] [Indexed: 06/09/2024]
Abstract
Comprehensive, continuous quantitative monitoring of intricately orchestrated physiological processes and behavioral states in living organisms can yield essential data for elucidating the function of neural circuits under healthy and diseased conditions, for defining the effects of potential drugs and treatments, and for tracking disease progression and recovery. Here, we report a wireless, battery-free implantable device and a set of associated algorithms that enable continuous, multiparametric physio-behavioral monitoring in freely behaving small animals and interacting groups. Through advanced analytics approaches applied to mechano-acoustic signals of diverse body processes, the device yields heart rate, respiratory rate, physical activity, temperature, and behavioral states. Demonstrations in pharmacological, locomotor, and acute and social stress tests and in optogenetic studies offer unique insights into the coordination of physio-behavioral characteristics associated with healthy and perturbed states. This technology has broad utility in neuroscience, physiology, behavior, and other areas that rely on studies of freely moving, small animal models.
Collapse
Affiliation(s)
- Wei Ouyang
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA; Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA
| | - Keith J Kilner
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA; NeuroLux Inc., Northfield, IL 60093, USA
| | | | - Yiming Liu
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA
| | - Yinsheng Lu
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA
| | | | - Kayla M Pitts
- Department of Biological Structure, University of Washington, Seattle, WA 98195, USA
| | - Mingzheng Wu
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA
| | | | - Ian Jones
- NeuroLux Inc., Northfield, IL 60093, USA
| | - Yunyun Wu
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA
| | - Haiwen Luan
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA
| | - Jacob Trueb
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA
| | | | - Iwona Stepien
- Developmental Therapeutics Core, Northwestern University, Evanston, IL 60208, USA
| | | | - Chad R Haney
- Center for Advanced Molecular Imaging, Northwestern University, Evanston, IL 60208, USA
| | - Hao Li
- Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Evanston, IL 60208, USA; Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Evanston, IL 60208, USA
| | - Yevgenia Kozorovitskiy
- Department of Neurobiology, Northwestern University, Evanston, IL 60208, USA; Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA
| | - Mitra Heshmati
- Department of Biological Structure, University of Washington, Seattle, WA 98195, USA; Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle, WA 98195, USA; Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA 98195, USA
| | - Anthony R Banks
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA; NeuroLux Inc., Northfield, IL 60093, USA
| | - Sam A Golden
- Department of Biological Structure, University of Washington, Seattle, WA 98195, USA; Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle, WA 98195, USA.
| | - Cameron H Good
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA; NeuroLux Inc., Northfield, IL 60093, USA.
| | - John A Rogers
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL 60208, USA; Department of Materials Science and Engineering, Northwestern University, Evanston, IL 60208, USA; Department of Mechanical Engineering, Northwestern University, Evanston, IL 60208, USA; Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA; Department of Chemistry, Northwestern University, Evanston, IL 60208, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Evanston, IL 60208, USA.
| |
Collapse
|
2
|
Jaini R, Lin J, Di L, Sagawa K. PBPK Modeling of PAXLOVID TM: Incorporating Rotamer Conversion Kinetics to Advanced Dissolution and Absorption Model. J Pharm Sci 2024; 113:64-71. [PMID: 37805075 DOI: 10.1016/j.xphs.2023.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 09/28/2023] [Accepted: 09/29/2023] [Indexed: 10/09/2023]
Abstract
PAXLOVID™ is a combination medicine of nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir is a peptidomimetic inhibitor of SARS-CoV2 main protease (Mpro), developed for the treatment of COVID-19. Ritonavir is co-administered as a pharmacokinetics (PK) enhancer to inhibit CYP3A mediated metabolism increasing exposures of nirmatrelvir. In the solid form, nirmatrelvir exists in a stable single conformational state (ANTI form). However, nirmatrelvir exhibits atropisomerism in solution whereby upon dissolution the ANTI rotational isomer reversibly converts to another conformation state (SYN form). Nirmatrelvir rotamer conversion follows pseudo first order kinetics with a conversion half-life of approximately 15 min in aqueous solutions, which is on a similar time scale of diffusion mediated dissolution from the solid form. In vitro dissolution studies further indicated that rotamer conversion is one of the processes controlling nirmatrelvir dissolution. It was hypothesized that rotamer conversion kinetics would affect oral absorption of nirmatrelvir in vivo. Consequently, a physiologically based pharmacokinetic (PBPK) model for Paxlovid was developed in Simcyp™ using the advanced dissolution, absorption, and metabolism model (ADAM) by incorporating rotamer conversion kinetics to achieve a more mechanistic description of nirmatrelvir oral absorption. The results demonstrate that the established absorption model with rotamer kinetics adequately described observed clinical data from various nirmatrelvir doses, dosage forms, and dosing regimens. The predicted vs. observed AUCinf and Cmax ratios were within 2-fold. The model has been internally used to inform clinical studies and dose recommendations for pediatrics.
Collapse
Affiliation(s)
- Rohit Jaini
- Drug Product Design, Pharmaceutical Sciences Small Molecule, Pfizer Inc., Cambridge, MA 02139, United States
| | - Jian Lin
- Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, CT 06340, United States
| | - Li Di
- Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, CT 06340, United States
| | - Kazuko Sagawa
- Drug Product Design, Pharmaceutical Sciences Small Molecule, Pfizer Inc., Groton, CT 06340, United States.
| |
Collapse
|
3
|
Cirilli M, Maroni A, Moutaharrik S, Foppoli A, Ochoa E, Palugan L, Gazzaniga A, Cerea M. Organ-Retentive Osmotically Driven System (ORODS): A Novel Expandable Platform for in Situ Drug Delivery. Int J Pharm 2023; 644:123295. [PMID: 37544386 DOI: 10.1016/j.ijpharm.2023.123295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 08/02/2023] [Accepted: 08/03/2023] [Indexed: 08/08/2023]
Abstract
Drug delivery systems capable of being retained within hollow organs allow the entire drug dose to be delivered locally to the disease site or to absorption windows for improved systemic bioavailability. A novel Organ-Retentive Osmotically Driven System (ORODS) was here proposed, obtained by assembling drug-containing units having prolonged release kinetics with osmotic units used as increasing volume compartments. Particularly, prototypes having H-shape design were conceived, manufactured and evaluated. Such devices were assembled by manually inserting a tube made of regenerated cellulose (osmotic unit) into the holes of two perforated hydrophilic tableted matrices containing paracetamol as a tracer drug. The osmotic unit was obtained by folding and gluing a plain regenerated cellulose membrane and loading sodium chloride inside. When immersed in aqueous fluids, this compartment expanded to approximately 80% of its maximum volume within 30 min of testing, and a plateau was maintained for about 6 h. Subsequently, it slowly shrank to approximately 20% of the maximum volume in 24 h, which would allow for physiological emptying of the device from hollow organs. While expanding, the osmotic unit acquired stiffness. Drug release from H-shaped ORODSs conveyed in hard-gelatin capsules was shown to be prolonged for more than 24 h.
Collapse
Affiliation(s)
- Micol Cirilli
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Alessandra Maroni
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Saliha Moutaharrik
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy.
| | - Anastasia Foppoli
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Evelyn Ochoa
- Università degli Studi di Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milan, Italy
| | - Luca Palugan
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Andrea Gazzaniga
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Matteo Cerea
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| |
Collapse
|
4
|
Straker MA, Levy JA, Stine JM, Borbash V, Beardslee LA, Ghodssi R. Freestanding region-responsive bilayer for functional packaging of ingestible devices. MICROSYSTEMS & NANOENGINEERING 2023; 9:61. [PMID: 37206701 PMCID: PMC10188515 DOI: 10.1038/s41378-023-00536-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 03/21/2023] [Accepted: 04/08/2023] [Indexed: 05/21/2023]
Abstract
Ingestible capsules have the potential to become an attractive alternative to traditional means of treating and detecting gastrointestinal (GI) disease. As device complexity increases, so too does the demand for more effective capsule packaging technologies to elegantly target specific GI locations. While pH-responsive coatings have been traditionally used for the passive targeting of specific GI regions, their application is limited due to the geometric restrictions imposed by standard coating methods. Dip, pan, and spray coating methods only enable the protection of microscale unsupported openings against the harsh GI environment. However, some emerging technologies have millimeter-scale components for performing functions such as sensing and drug delivery. To this end, we present the freestanding region-responsive bilayer (FRRB), a packaging technology for ingestible capsules that can be readily applied for various functional ingestible capsule components. The bilayer is composed of rigid polyethylene glycol (PEG) under a flexible pH-responsive Eudragit® FL 30 D 55, which protects the contents of the capsule until it arrives in the targeted intestinal environment. The FRRB can be fabricated in a multitude of shapes that facilitate various functional packaging mechanisms, some of which are demonstrated here. In this paper, we characterize and validate the use of this technology in a simulated intestinal environment, confirming that the FRRB can be tuned for small intestinal release. We also show a case example where the FRRB is used to protect and expose a thermomechanical actuator for targeted drug delivery.
Collapse
Affiliation(s)
- Michael A. Straker
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742 USA
- Institute for Systems Research, University of Maryland, College Park, MD 20740 USA
- Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20850 USA
| | - Joshua A. Levy
- Institute for Systems Research, University of Maryland, College Park, MD 20740 USA
- Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20850 USA
- Department of Material Science and Engineering, University of Maryland, College Park, MD 20740 USA
| | - Justin M. Stine
- Institute for Systems Research, University of Maryland, College Park, MD 20740 USA
- Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20850 USA
- Department of Electrical and Computer Engineering, University of Maryland, College Park, MD 20742 USA
| | - Vivian Borbash
- Department of Electrical and Computer Engineering, University of Maryland, College Park, MD 20742 USA
| | - Luke A. Beardslee
- Institute for Systems Research, University of Maryland, College Park, MD 20740 USA
| | - Reza Ghodssi
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742 USA
- Institute for Systems Research, University of Maryland, College Park, MD 20740 USA
- Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20850 USA
- Department of Electrical and Computer Engineering, University of Maryland, College Park, MD 20742 USA
| |
Collapse
|
5
|
Li Y, Kong F. Simulating human gastrointestinal motility in dynamic in vitro models. Compr Rev Food Sci Food Saf 2022; 21:3804-3833. [PMID: 35880687 DOI: 10.1111/1541-4337.13007] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 03/26/2022] [Accepted: 06/22/2022] [Indexed: 01/28/2023]
Abstract
The application of dynamic in vitro gastrointestinal (GI) models has grown in popularity to understand the impact of food structure and composition on human health. Given that GI motility is integral to digestion and absorption, a predictive in vitro model should faithfully replicate the motility patterns and motor functions in vivo. In this review, typical characteristics of gastric and small intestinal motility in humans as well as the biomechanical and hydrodynamic events pertinent to gut motility are summarized. The simulation of GI motility in the presently existing dynamic in vitro models is discussed from an engineering perspective and categorized into hydraulic, piston/probe-driven, roller-driven, pneumatic, and other systems. Each system and its representative models are evaluated in terms of their motility patterns, the key hydrodynamic characteristics concerning gut motility, their performance in simulating the key physiological events, and their ability to establish in vitro-in vivo correlations. Practical Application: The review paper provided useful information in the design of dynamic GI models and the simulation of human gastric and small intestinal motility which are important for understanding food and health.
Collapse
Affiliation(s)
- Yiwen Li
- Department of Food Science and Technology, College of Agricultural and Environmental Sciences, University of Georgia, Athens, Georgia, USA
| | - Fanbin Kong
- Department of Food Science and Technology, College of Agricultural and Environmental Sciences, University of Georgia, Athens, Georgia, USA
| |
Collapse
|
6
|
Phùng TTT, Gerometta M, Chanut J, Raise A, Ureña M, Dupont S, Beney L, Karbowiak T. Comprehensive approach to the protection and controlled release of extremely oxygen sensitive probiotics using edible polysaccharide-based coatings. Int J Biol Macromol 2022; 218:706-719. [PMID: 35872315 DOI: 10.1016/j.ijbiomac.2022.07.129] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 07/13/2022] [Accepted: 07/17/2022] [Indexed: 11/19/2022]
Abstract
The human intestinal system is a complex of various anaerobes including extremely oxygen-sensitive (EOS) bacteria, some of which have been credited with significant health benefits. Among these, Faecalibacterium prausnitzii, which is one of the most abundant anaerobic bacterial strains in the human intestinal tract, has been proved to be a promising probiotic for the treatment of inflammatory bowel diseases. However, because of its extremely sensitive nature, there are many difficulties when passing through the harsh environment of the gastrointestinal tract. Hence, in this study, a comprehensive physicochemical characterization was performed for the use of polysaccharides from several origins (hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl cellulose, chitosan, low-methoxylated pectin, kappa-carrageenan, sodium alginate and pullulan) as encapsulating agents to protect and deliver this bacterium. First, the apparent viscosity and surface tension of the polymer solutions were tested. Then, the mechanical properties, water vapor and oxygen barrier properties of these biopolymers as self-standing films were investigated. Lastly, in vitro release profiles of small molecules and bacterial cells from these biopolymer matrices in contact with a simulated gastrointestinal tract were evaluated. The results showed that chitosan, low-methoxylated pectin, kappa-carrageenan, sodium alginate and pullulan films exhibited good oxygen barrier properties to protect EOS probiotics. Among all the biopolymers tested, sodium alginate exhibited the best oxygen barrier properties and release profile. The release kinetics can be modulated by several factors including biopolymer type, plasticizer concentration and active molecules or bacteria to be encapsulated. On that basis and integrating the other parameters analyzed, a multicriteria strategy for probiotic encapsulation was proposed.
Collapse
Affiliation(s)
- Thị-Thanh-Trúc Phùng
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - Massimiliano Gerometta
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - Julie Chanut
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - Audrey Raise
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - María Ureña
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - Sébastien Dupont
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - Laurent Beney
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France
| | - Thomas Karbowiak
- Univ. Bourgogne Franche-Comté, Institut Agro Dijon, PAM UMR 02 102, 1 Esplanade Erasme, 21000 Dijon, France.
| |
Collapse
|
7
|
Sarker S, Wankum B, Perey T, Mau MM, Shimizu J, Jones R, Terry B. A Novel Capsule-Delivered Enteric Drug-Injection Device for Delivery of Systemic Biologics: A Pilot Study in a Porcine Model. IEEE Trans Biomed Eng 2021; 69:1870-1879. [PMID: 34807818 DOI: 10.1109/tbme.2021.3129653] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Innovative swallowable capsule technologies such as drug-loaded, dissolvable microneedles, mucoadhesive patches, and various microdevices present unique drug-carrying capabilities to overcome challenges regarding oral delivery of biologics. Here, we report a swallowable capsule for intestinal drug delivery (SCIDD) with the potential of directly injecting biological therapeutics into the insensate small intestine wall. The design, optimization, and validation of the SCIDD's primary subsystems were performed both ex-vivo and in-vivo. The assembled capsule was further tested in vivo to validate the actuation sequence and showed a 70% (n=17) success rate in an animal model. Additionally, a drug delivery study indicated systemic uptake of adalimumab via SCIDD compared with luminal delivery in the small intestine. The pilot study presented here establishes that the novel platform could be used to orally deliver systemic biologics.
Collapse
|
8
|
Stamatopoulos K, O'Farrell C, Simmons M, Batchelor H. In vivo models to evaluate ingestible devices: Present status and current trends. Adv Drug Deliv Rev 2021; 177:113915. [PMID: 34371085 DOI: 10.1016/j.addr.2021.113915] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 07/27/2021] [Accepted: 08/02/2021] [Indexed: 12/12/2022]
Abstract
Evaluation of orally ingestible devices is critical to optimize their performance early in development. Using animals as a pre-clinical tool can provide useful information on functionality, yet it is important to recognize that animal gastrointestinal physiology, pathophysiology and anatomy can differ to that in humans and that the most suitable species needs to be selected to inform the evaluation. There has been a move towards in vitro and in silico models rather than animal models in line with the 3Rs (Replacement, Reduction and Refinement) as well as the better control and reproducibility associated with these systems. However, there are still instances where animal models provide the greatest understanding. This paper provides an overview of key aspects of human gastrointestinal anatomy and physiology and compares parameters to those reported in animal species. The value of each species can be determined based upon the parameter of interest from the ingested device when considering the use of pre-clinical animal testing.
Collapse
Affiliation(s)
- Konstantinos Stamatopoulos
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; Biopharmaceutics, Pharmaceutical Development, PDS, MST, RD Platform Technology & Science, GSK, David Jack Centre, Park Road, Ware, Hertfordshire SG12 0DP, UK
| | - Connor O'Farrell
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - Mark Simmons
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - Hannah Batchelor
- Strathclyde Institute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow G4 0RE, UK.
| |
Collapse
|
9
|
Luo Z, Paunović N, Leroux JC. Physical methods for enhancing drug absorption from the gastrointestinal tract. Adv Drug Deliv Rev 2021; 175:113814. [PMID: 34052229 DOI: 10.1016/j.addr.2021.05.024] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 05/17/2021] [Accepted: 05/20/2021] [Indexed: 01/01/2023]
Abstract
Overcoming the gastrointestinal (GI) barriers is a formidable challenge in the oral delivery of active macromolecules such as peptide- and protein- based drugs. In the past four decades, a plethora of formulation strategies ranging from permeation enhancers, nanosized carriers, and chemical modifications of the drug's structure has been investigated to increase the oral absorption of these macromolecular compounds. However, only limited successes have been achieved so far, with the bioavailability of marketed oral peptide drugs remaining generally very low. Recently, a few approaches that are based on physical interactions, such as magnetic, acoustic, and mechanical forces, have been explored in order to control and improve the drug permeability across the GI mucosa. Although in the early stages, some of these methods have shown great potential both in terms of improved bioavailability and spatiotemporal delivery of drugs. Here, we offer a concise, yet critical overview of these rather unconventional technologies with a particular focus on their potential and possible challenges for further clinical translation.
Collapse
|
10
|
Martinez MN, Mochel JP, Neuhoff S, Pade D. Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics. AAPS JOURNAL 2021; 23:59. [PMID: 33907906 DOI: 10.1208/s12248-021-00590-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 03/30/2021] [Indexed: 02/06/2023]
Abstract
This review is a summary of factors affecting the drug pharmacokinetics (PK) of dogs versus humans. Identifying these interspecies differences can facilitate canine-human PK extrapolations while providing mechanistic insights into species-specific drug in vivo behavior. Such a cross-cutting perspective can be particularly useful when developing therapeutics targeting diseases shared between the two species such as cancer, diabetes, cognitive dysfunction, and inflammatory bowel disease. Furthermore, recognizing these differences also supports a reverse PK extrapolations from humans to dogs. To appreciate the canine-human differences that can affect drug absorption, distribution, metabolism, and elimination, this review provides a comparison of the physiology, drug transporter/enzyme location, abundance, activity, and specificity between dogs and humans. Supplemental material provides an in-depth discussion of certain topics, offering additional critical points to consider. Based upon an assessment of available state-of-the-art information, data gaps were identified. The hope is that this manuscript will encourage the research needed to support an understanding of similarities and differences in human versus canine drug PK.
Collapse
Affiliation(s)
- Marilyn N Martinez
- Office of New Animal Drug Evaluation, Center for Veterinary Medicine, Food and Drug Administration, Rockville, Maryland, 20855, USA.
| | - Jonathan P Mochel
- SMART Pharmacology, Department of Biomedical Sciences, Iowa State University, Ames, Iowa, 50011, USA
| | - Sibylle Neuhoff
- Certara UK Limited, Simcyp Division, 1 Concourse Way, Sheffield, S1 2BJ, UK
| | - Devendra Pade
- Certara UK Limited, Simcyp Division, 1 Concourse Way, Sheffield, S1 2BJ, UK
| |
Collapse
|
11
|
Abramson A, Dellal D, Kong YL, Zhou J, Gao Y, Collins J, Tamang S, Wainer J, McManus R, Hayward A, Frederiksen MR, Water JJ, Jensen B, Roxhed N, Langer R, Traverso G. Ingestible transiently anchoring electronics for microstimulation and conductive signaling. SCIENCE ADVANCES 2020; 6:eaaz0127. [PMID: 32923616 PMCID: PMC7455191 DOI: 10.1126/sciadv.aaz0127] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2019] [Accepted: 07/16/2020] [Indexed: 05/03/2023]
Abstract
Ingestible electronic devices enable noninvasive evaluation and diagnosis of pathologies in the gastrointestinal (GI) tract but generally cannot therapeutically interact with the tissue wall. Here, we report the development of an orally administered electrical stimulation device characterized in ex vivo human tissue and in in vivo swine models, which transiently anchored itself to the stomach by autonomously inserting electrically conductive, hooked probes. The probes provided stimulation to the tissue via timed electrical pulses that could be used as a treatment for gastric motility disorders. To demonstrate interaction with stomach muscle tissue, we used the electrical stimulation to induce acute muscular contractions. Pulses conductively signaled the probes' successful anchoring and detachment events to a parenterally placed device. The ability to anchor into and electrically interact with targeted GI tissues controlled by the enteric nervous system introduces opportunities to treat a multitude of associated pathologies.
Collapse
Affiliation(s)
- Alex Abramson
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - David Dellal
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Yong Lin Kong
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Department of Mechanical Engineering, University of Utah, Salt Lake City, UT 84112, USA
| | - Jianlin Zhou
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Yuan Gao
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Joy Collins
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Siddartha Tamang
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jacob Wainer
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Rebecca McManus
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Alison Hayward
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - Jorrit J. Water
- Global Research Technologies and Device R&D, Novo Nordisk A/S, Maaloev, Denmark
| | - Brian Jensen
- Global Research Technologies and Device R&D, Novo Nordisk A/S, Maaloev, Denmark
| | - Niclas Roxhed
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Department of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Robert Langer
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Corresponding author. (R.L.); (G.T.)
| | - Giovanni Traverso
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Corresponding author. (R.L.); (G.T.)
| |
Collapse
|
12
|
Babaee S, Pajovic S, Kirtane AR, Shi J, Caffarel-Salvador E, Hess K, Collins JE, Tamang S, Wahane AV, Hayward AM, Mazdiyasni H, Langer R, Traverso G. Temperature-responsive biometamaterials for gastrointestinal applications. Sci Transl Med 2020; 11:11/488/eaau8581. [PMID: 30996082 PMCID: PMC7797624 DOI: 10.1126/scitranslmed.aau8581] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2018] [Revised: 12/13/2018] [Accepted: 03/22/2019] [Indexed: 12/12/2022]
Abstract
We hypothesized that ingested warm fluids could act as triggers for biomedical devices. We investigated heat dissipation throughout the upper gastrointestinal (GI) tract by administering warm (55°C) water to pigs and identified two zones in which thermal actuation could be applied: esophageal (actuation through warm water ingestion) and extra-esophageal (protected from ingestion of warm liquids and actuatable by endoscopically administered warm fluids). Inspired by a blooming flower, we developed a capsule-sized esophageal system that deploys using elastomeric elements and then recovers its original shape in response to thermal triggering of shape-memory nitinol springs by ingestion of warm water. Degradable millineedles incorporated into the system could deliver model molecules to the esophagus. For the extra-esophageal compartment, we developed a highly flexible macrostructure (mechanical metamaterial) that deforms into a cylindrical shape to safely pass through the esophagus and deploys into a fenestrated spherical shape in the stomach, capable of residing safely in the gastric cavity for weeks. The macrostructure uses thermoresponsive elements that dissociate when triggered with the endoscopic application of warm (55°C) water, allowing safe passage of the components through the GI tract. Our gastric-resident platform acts as a gram-level long-lasting drug delivery dosage form, releasing small-molecule drugs for 2 weeks. We anticipate that temperature-triggered systems could usher the development of the next generation of stents, drug delivery, and sensing systems housed in the GI tract.
Collapse
Affiliation(s)
- Sahab Babaee
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Simo Pajovic
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ameya R Kirtane
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jiuyun Shi
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ester Caffarel-Salvador
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Kaitlyn Hess
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Joy E Collins
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Siddartha Tamang
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Aniket V Wahane
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Alison M Hayward
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Hormoz Mazdiyasni
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Robert Langer
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. .,Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Giovanni Traverso
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. .,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
13
|
Gao Z, Tian L, Rodriguez JD. Nifedipine Release From Extended-Release Solid Oral Formulations Using In Vitro Dissolution Testing Under Simulated Gastrointestinal Compression. J Pharm Sci 2020; 109:2173-2179. [PMID: 32240693 DOI: 10.1016/j.xphs.2020.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 03/20/2020] [Accepted: 03/23/2020] [Indexed: 10/24/2022]
Abstract
Drug release plays a critical role in defining bioavailability for an extended release solid oral drug products and predictive dissolution tests are desired to establish clinically relevant quality standards for batch release. The objective of this study focuses on exploring the possible impacts of 1 gastrointestinal (GI) parameter for 1 drug: simulated GI contractions on nifedipine release (in 2 extended release solid oral formulations). The 60 mg nifedipine osmotic pump product A, and polymer matrix-based products B and C were examined in the study. An in-house dissolution system was used to simulate various levels of GI contractions on tested samples, and to monitor changes of sample mechanical properties during dissolution testing. The results show that the polymer matrix-based formulation failed to provide controlled release when simulated GI contraction was above 100 g of force. The method may be useful for polymer matrix-based products to assess potential formulation-related interactions with the GI tract during in vivo drug dissolution.
Collapse
Affiliation(s)
- Zongming Gao
- Division of Pharmaceutical Analysis, Food and Drug Administration, Center for Drug Evaluation and Research, St. Louis, Missouri 63110.
| | - Li Tian
- Division of Pharmaceutical Analysis, Food and Drug Administration, Center for Drug Evaluation and Research, St. Louis, Missouri 63110
| | - Jason D Rodriguez
- Division of Pharmaceutical Analysis, Food and Drug Administration, Center for Drug Evaluation and Research, St. Louis, Missouri 63110
| |
Collapse
|
14
|
Martinez AF, Sinha K, Nere N, Slade R, Castleberry S. Characterization of the Hydrodynamics in the USP Basket Apparatus Using Computational Fluid Dynamics. J Pharm Sci 2020; 109:1231-1241. [DOI: 10.1016/j.xphs.2019.11.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 10/14/2019] [Accepted: 11/07/2019] [Indexed: 10/25/2022]
|
15
|
Lowinger MB, Maier EY, Williams RO, Zhang F. Hydrophilic Poly(urethanes) Are an Effective Tool for Gastric Retention Independent of Drug Release Rate. J Pharm Sci 2020; 109:1967-1977. [PMID: 32087181 DOI: 10.1016/j.xphs.2020.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/12/2019] [Accepted: 02/05/2020] [Indexed: 11/28/2022]
Abstract
Acyclovir is a poorly permeable, short half-life drug with poor colonic absorption, and current conventional controlled release formulations are unable to decrease the frequency of administration. We designed acyclovir dosage forms to be administered less frequently by being retained in the stomach and releasing drug over an extended duration. We developed a conventional modified-release matrix tablet to sustain the release of acyclovir and surrounded it with a hydrophilic poly(urethane) layer. When hydrated, the porous poly(urethane) swells to a size near or beyond that of the relaxed pylorus diameter and does not affect drug release rate. We demonstrated that the formulation is retained in the stomach for extended durations as it slowly releases drug, allowing for similar area under the curve but delayed tmax relative to a nongastroretentive control tablet. Unlike many other gastroretentive formulations, this dosage form design decouples drug release rate from gastric retention time, allowing them to be modulated independently. It also effectively retains in the stomach regardless of the prandial state, differentiating from other approaches. Our direct observation of excised rat stomachs allowed for a rigorous assessment of the impact of polymer swelling extent and the prandial state on both the dosage form integrity and retention time.
Collapse
Affiliation(s)
- Michael B Lowinger
- Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, Texas 78712; MRL, Merck & Co, Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065
| | - Esther Y Maier
- Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, Texas 78712
| | - Robert O Williams
- Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, Texas 78712
| | - Feng Zhang
- Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, Texas 78712.
| |
Collapse
|
16
|
Verma M, Vishwanath K, Eweje F, Roxhed N, Grant T, Castaneda M, Steiger C, Mazdiyasni H, Bensel T, Minahan D, Soares V, Salama JAF, Lopes A, Hess K, Cleveland C, Fulop DJ, Hayward A, Collins J, Tamang SM, Hua T, Ikeanyi C, Zeidman G, Mule E, Boominathan S, Popova E, Miller JB, Bellinger AM, Collins D, Leibowitz D, Batra S, Ahuja S, Bajiya M, Batra S, Sarin R, Agarwal U, Khaparde SD, Gupta NK, Gupta D, Bhatnagar AK, Chopra KK, Sharma N, Khanna A, Chowdhury J, Stoner R, Slocum AH, Cima MJ, Furin J, Langer R, Traverso G. A gastric resident drug delivery system for prolonged gram-level dosing of tuberculosis treatment. Sci Transl Med 2020; 11:11/483/eaau6267. [PMID: 30867322 PMCID: PMC7797620 DOI: 10.1126/scitranslmed.aau6267] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Accepted: 02/01/2019] [Indexed: 12/12/2022]
Abstract
Multigram drug depot systems for extended drug release could transform our capacity to effectively treat patients across a myriad of diseases. For example, tuberculosis (TB) requires multimonth courses of daily multigram doses for treatment. To address the challenge of prolonged dosing for regimens requiring multigram drug dosing, we developed a gastric resident system delivered through the nasogastric route that was capable of safely encapsulating and releasing grams of antibiotics over a period of weeks. Initial preclinical safety and drug release were demonstrated in a swine model with a panel of TB antibiotics. We anticipate multiple applications in the field of infectious diseases, as well as for other indications where multigram depots could impart meaningful benefits to patients, helping maximize adherence to their medication.
Collapse
Affiliation(s)
- Malvika Verma
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Karan Vishwanath
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Feyisope Eweje
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Niclas Roxhed
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm 10044, Sweden
| | - Tyler Grant
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Macy Castaneda
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Christoph Steiger
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Hormoz Mazdiyasni
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Taylor Bensel
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Daniel Minahan
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Vance Soares
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - John A F Salama
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Aaron Lopes
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Kaitlyn Hess
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Cody Cleveland
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Daniel J Fulop
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Alison Hayward
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Joy Collins
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Siddartha M Tamang
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Tiffany Hua
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Chinonyelum Ikeanyi
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Gal Zeidman
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Elizabeth Mule
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Sooraj Boominathan
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ellena Popova
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jonathan B Miller
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Andrew M Bellinger
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Cardiovascular Division, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - David Collins
- Management Sciences for Health, Medford, MA 02155, USA.,Boston University School of Public Health, Boston, MA 02118, USA
| | - Dalia Leibowitz
- Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | | | | | | | - Rohit Sarin
- National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India
| | - Upasna Agarwal
- National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India
| | - Sunil D Khaparde
- Former Deputy Director General and Head of Central TB Division, Government of India, New Delhi 110011, India
| | - Neeraj K Gupta
- Department of Respiratory Medicine, Safdarjung Hospital, New Delhi 110029, India
| | - Deepak Gupta
- Division of Pulmonary and Critical Care Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Anuj K Bhatnagar
- Rajan Babu Institute for Pulmonary Medicine and Tuberculosis, New Delhi 110009, India
| | | | - Nandini Sharma
- Department of Community Medicine, Maulana Azad Medical College, New Delhi 110002, India
| | - Ashwani Khanna
- Lok Nayak Hospital Chest Clinic, New Delhi 110002, India
| | | | - Robert Stoner
- Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,MIT Energy Initiative, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Alexander H Slocum
- Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Michael J Cima
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jennifer Furin
- Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Robert Langer
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. .,Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Giovanni Traverso
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. .,Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| |
Collapse
|
17
|
Schneider F, Koziolek M, Weitschies W. In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms. Pharmaceutics 2019; 11:E416. [PMID: 31426417 PMCID: PMC6723944 DOI: 10.3390/pharmaceutics11080416] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 08/07/2019] [Accepted: 08/12/2019] [Indexed: 12/16/2022] Open
Abstract
More than 50 years ago, the first concepts for gastroretentive drug delivery systems were developed. Despite extensive research in this field, there is no single formulation concept for which reliable gastroretention has been demonstrated under different prandial conditions. Thus, gastroretention remains the holy grail of oral drug delivery. One of the major reasons for the various setbacks in this field is the lack of predictive in vitro and in vivo test methods used during preclinical development. In most cases, human gastrointestinal physiology is not properly considered, which leads to the application of inappropriate in vitro and animal models. Moreover, conditions in the stomach are often not fully understood. Important aspects such as the kinetics of fluid volumes, gastric pH or mechanical stresses have to be considered in a realistic manner, otherwise, the gastroretentive potential as well as drug release of novel formulations cannot be assessed correctly in preclinical studies. This review, therefore, highlights the most important aspects of human gastrointestinal physiology and discusses their potential implications for the evaluation of gastroretentive drug delivery systems.
Collapse
Affiliation(s)
- Felix Schneider
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany
| | - Mirko Koziolek
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany
| | - Werner Weitschies
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.
| |
Collapse
|
18
|
Kanasty R, Low S, Bhise N, Yang J, Peeke E, Schwarz M, Wright J, Carter B, Moorthy S, Grant T, DeBenedictis B, Bishoff M, Simses C, Bellinger AM. A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease. J Control Release 2019; 303:34-41. [PMID: 30928488 PMCID: PMC6587581 DOI: 10.1016/j.jconrel.2019.03.022] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Accepted: 03/25/2019] [Indexed: 10/27/2022]
Abstract
Adherence to medication regimens is a major barrier to effective treatment in many disease areas, notably in dementia which causes cognitive impairment that reduces patients' awareness of non-adherence and their ability to manage medication. The development of oral dosage forms that can be infrequently dosed, and therefore improve adherence rate and facilitate direct observed therapy, has been a goal for decades. We describe the first demonstration of an oral formulation that achieves >7-day gastric retention and sustained pharmacokinetics in the challenging dog model. Gastric retention requires physical resistance of the dosage form to gastric emptying forces, which are known to be stronger in dogs than in humans, making successful gastric retention in dogs a stringent test for predicting human translatability. This formulation of memantine hydrochloride is the first oral dosage form that achieves multi-day drug release with near zero-order kinetics and efficient delivery. In the dog model, relative memantine bioavailability approaches 100% with sustained plasma levels of memantine over seven days and profiles that can be tuned by varying components of the formulation. A single gastric resident dosage form achieves an AUC equivalent to 7 daily treatments with the marketed daily capsule, with a Cmax that is no higher than the daily product. PK modeling predicts that the gastroretentive formulation will maintain therapeutic blood levels in humans when administered once weekly. The formulation methodology presented here is applicable to many water soluble drugs and may enable the development of long-acting oral therapies for a wide variety of conditions.
Collapse
Affiliation(s)
- Rosemary Kanasty
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Susan Low
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Nupura Bhise
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Jung Yang
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Erick Peeke
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Marlene Schwarz
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - James Wright
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Bennett Carter
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Saumya Moorthy
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Tyler Grant
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Ben DeBenedictis
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Megan Bishoff
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Craig Simses
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America
| | - Andrew M Bellinger
- Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02471, United States of America; Brigham and Women's Division of Cardiovascular Medicine, 75 Francis St, Boston, MA 02115, United States of America.
| |
Collapse
|
19
|
Simons FJ, Wagner KG. Modeling, design and manufacture of innovative floating gastroretentive drug delivery systems based on hot-melt extruded tubes. Eur J Pharm Biopharm 2019; 137:196-208. [PMID: 30826475 DOI: 10.1016/j.ejpb.2019.02.022] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 02/23/2019] [Accepted: 02/26/2019] [Indexed: 01/07/2023]
Abstract
The problem of many gastroretentive systems is the mechanistic connection of drug release and gastric retention control. This connection could be successfully separated by formulating hollow tubes via hot-melt extrusion and sealing both tube ends, which led to immediately floating devices. The tube wall consisted of metformin crystals embedded in an inert polymer matrix of Eudragit® RS PO and E PO. Very high drug loadings of up to 80% (w/w) were used without generating a 'burst release'. Sustained release profiles from four to more than twelve hours were achieved by varying the polymer proportions without affecting the floatability. Buoyancy was found to mainly depend on the cylinder design, i.e. the outer to inner diameter ratio. This allowed the polymer/metformin composition to be changed without affecting buoyancy, i.e. a separation of floatability and release control was achieved. A prediction model was implemented that allowed for the buoyancy force to be determined with high accuracy by selecting a suitable ratio of outer to inner diameter of the modular tube die. Wall thickness and mass normalized surface area were identified as geometric parameters that mainly influenced the release properties. Conclusively, this study offers a highly flexible and rational manufacturing approach for the development of gastroretentive floating drug delivery systems.
Collapse
Affiliation(s)
- Fabian J Simons
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Bonn, Germany
| | - Karl G Wagner
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Bonn, Germany.
| |
Collapse
|
20
|
Kong YL, Zou X, McCandler CA, Kirtane AR, Ning S, Zhou J, Abid A, Jafari M, Rogner J, Minahan D, Collins JE, McDonnell S, Cleveland C, Bensel T, Tamang S, Arrick G, Gimbel A, Hua T, Ghosh U, Soares V, Wang N, Wahane A, Hayward A, Zhang S, Smith BR, Langer R, Traverso G. 3D-Printed Gastric Resident Electronics. ADVANCED MATERIALS TECHNOLOGIES 2018; 4:1800490. [PMID: 32010758 PMCID: PMC6988123 DOI: 10.1002/admt.201800490] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2018] [Revised: 11/06/2018] [Indexed: 05/20/2023]
Abstract
Long-term implantation of biomedical electronics into the human body enables advanced diagnostic and therapeutic functionalities. However, most long-term resident electronics devices require invasive procedures for implantation as well as a specialized receiver for communication. Here, a gastric resident electronic (GRE) system that leverages the anatomical space offered by the gastric environment to enable residence of an orally delivered platform of such devices within the human body is presented. The GRE is capable of directly interfacing with portable consumer personal electronics through Bluetooth, a widely adopted wireless protocol. In contrast to the passive day-long gastric residence achieved with prior ingestible electronics, advancement in multimaterial prototyping enables the GRE to reside in the hostile gastric environment for a maximum of 36 d and maintain ≈15 d of wireless electronics communications as evidenced by the studies in a porcine model. Indeed, the synergistic integration of reconfigurable gastric-residence structure, drug release modules, and wireless electronics could ultimately enable the next-generation remote diagnostic and automated therapeutic strategies.
Collapse
Affiliation(s)
- Yong Lin Kong
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
| | - Xingyu Zou
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Caitlin A. McCandler
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Ameya R. Kirtane
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Shen Ning
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
| | - Jianlin Zhou
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Abubakar Abid
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Mousa Jafari
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Jaimie Rogner
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Daniel Minahan
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Joy E. Collins
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Shane McDonnell
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Cody Cleveland
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Taylor Bensel
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Siid Tamang
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Graham Arrick
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Alla Gimbel
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Tiffany Hua
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Udayan Ghosh
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
| | - Vance Soares
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Nancy Wang
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Aniket Wahane
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Alison Hayward
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Shiyi Zhang
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Brian R. Smith
- Department of Mechanical Engineering University of Utah Salt Lake City, UT 84112, USA
- Boston University School of Medicine 72 E Concord St, Boston, MA 02118, USA
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
- Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge, MA 02139, USA
| | - Robert Langer
- Charles Stark Draper Laboratory Cambridge, MA 02139, USA
| | - Giovanni Traverso
- Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge, MA 02139, USA
- Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School Boston, MA 02115, USA
| |
Collapse
|
21
|
Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets. J Pharm Sci 2018; 108:1189-1194. [PMID: 30343136 DOI: 10.1016/j.xphs.2018.10.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 09/17/2018] [Accepted: 10/11/2018] [Indexed: 12/24/2022]
Abstract
In contrast to nifedipine matrix-based extended-release dosage forms, the osmotic pump drug delivery systems have a zero-order drug release independent of external variables such as pH, agitation rate, and dissolution media. The objective of this study focuses on the in vitro evaluation of the mechanical properties of osmotic pump and polymer matrix-based formulations in dissolution media, and the potential impacts that media pH and simulated gastrointestinal contraction have on drug release. Two strengths of osmotic pump product A and polymer matrix-based product B were used in this study. An in-house system was developed with the capability of applying mechanical compression and monitoring mechanical properties of sample during dissolution testing. A United States Pharmacopeia or an in-house apparatus was used for dissolution testing under various conditions. Compared to the product A, the mechanical properties of the product B change significantly at various pHs and mechanical compressions. The results suggest that polymer matrix-based products bear a risk of formulation-related interactions with the gastrointestinal tract during in vivo drug dissolution, especially in the case of concomitant pH and gastric contractile changes. Modified dissolution testing devices may help formulation scientists in product development and provide regulatory agencies with an additional metric for quality assurance of drug products.
Collapse
|
22
|
3D printed capsules for quantitative regional absorption studies in the GI tract. Int J Pharm 2018; 550:418-428. [DOI: 10.1016/j.ijpharm.2018.08.055] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 08/21/2018] [Accepted: 08/28/2018] [Indexed: 12/14/2022]
|
23
|
Klein S, Seeger N, Mehta R, Missaghi S, Grybos R, Rajabi-Siahboomi A. Robustness of barrier membrane coated metoprolol tartrate matrix tablets: Drug release evaluation under physiologically relevant in vitro conditions. Int J Pharm 2018; 543:368-375. [PMID: 29630933 DOI: 10.1016/j.ijpharm.2018.04.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 03/16/2018] [Accepted: 04/04/2018] [Indexed: 11/15/2022]
Abstract
Robust in vitro drug release behavior is an important feature of extended release (ER) hydrophilic matrix formulations for accurate prediction of in vivo drug release. In this study, ER hydrophilic matrix tablets of metoprolol tartrate were formulated using a high viscosity grade of hypromellose as a rate-limiting polymer. Expectedly, this formulation showed an undesirable initial burst release followed by controlled drug release. Application of a barrier membrane (BM) coating of ethylcellulose with a pore former (hypromellose) resulted in the elimination of the burst effect. The aim of this study was to investigate the robustness of in vitro metoprolol release from BM-coated hydrophilic matrix tablets by simulating the physicochemical properties of gastrointestinal fluids and mechanical stress in the fasted- and fed state human gastrointestinal (GI) tract. Uncoated and BM-coated matrices were subjected to various dissolution studies simulating the varying pH conditions and additional physicochemical parameters, and the mechanical stress that can be caused by GI motility during both fasted and fed state GI passage. The BM-coated formulation showed robust drug release without an initial burst in all test scenarios. BM-coated matrix formulations thus represent a very promising approach for obtaining a highly controlled and robust drug release from oral ER formulations.
Collapse
Affiliation(s)
- Sandra Klein
- Ernst Moritz Arndt University, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, 3 Felix Hausdorff Street, Greifswald 17489, Germany.
| | - Nicole Seeger
- Ernst Moritz Arndt University, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, 3 Felix Hausdorff Street, Greifswald 17489, Germany
| | - Raxit Mehta
- Colorcon Inc., Global Headquarters, 275 Ruth Road, Harleysville, PA 19438, USA
| | - Shahrzad Missaghi
- Colorcon Inc., Global Headquarters, 275 Ruth Road, Harleysville, PA 19438, USA
| | - Relindis Grybos
- Ernst Moritz Arndt University, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, 3 Felix Hausdorff Street, Greifswald 17489, Germany
| | | |
Collapse
|
24
|
Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YAL, Mazdiyasni H, Kogan L, Barman R, Cleveland C, Booth L, Bensel T, Minahan D, Hurowitz HM, Tai T, Daily J, Nikolic B, Wood L, Eckhoff PA, Langer R, Traverso G. Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals. Sci Transl Med 2017; 8:365ra157. [PMID: 27856796 DOI: 10.1126/scitranslmed.aag2374] [Citation(s) in RCA: 152] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Accepted: 10/25/2016] [Indexed: 12/29/2022]
Abstract
Efforts at elimination of scourges, such as malaria, are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. We have developed an oral, ultra-long-acting capsule that dissolves in the stomach and deploys a star-shaped dosage form that releases drug while assuming a geometry that prevents passage through the pylorus yet allows passage of food, enabling prolonged gastric residence. This gastric-resident, drug delivery dosage form releases small-molecule drugs for days to weeks and potentially longer. Upon dissolution of the macrostructure, the components can safely pass through the gastrointestinal tract. Clinical, radiographic, and endoscopic evaluation of a swine large-animal model that received these dosage forms showed no evidence of gastrointestinal obstruction or mucosal injury. We generated long-acting formulations for controlled release of ivermectin, a drug that targets malaria-transmitting mosquitoes, in the gastric environment and incorporated these into our dosage form, which then delivered a sustained therapeutic dose of ivermectin for up to 14 days in our swine model. Further, by using mathematical models of malaria transmission that incorporate the lethal effect of ivermectin against malaria-transmitting mosquitoes, we demonstrated that this system will boost the efficacy of mass drug administration toward malaria elimination goals. Encapsulated, gastric-resident dosage forms for ultra-long-acting drug delivery have the potential to revolutionize treatment options for malaria and other diseases that affect large populations around the globe for which treatment adherence is essential for efficacy.
Collapse
Affiliation(s)
- Andrew M Bellinger
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.,Lyndra Inc., Watertown, MA 02472, USA
| | - Mousa Jafari
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Tyler M Grant
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Lyndra Inc., Watertown, MA 02472, USA
| | - Shiyi Zhang
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Hannah C Slater
- Department of Infectious Disease Epidemiology, MRC (Medical Research Council) Centre for Outbreak Analysis and Modelling, Imperial College London, London, U.K
| | | | - Stacy Mo
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Young-Ah Lucy Lee
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Hormoz Mazdiyasni
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Lawrence Kogan
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ross Barman
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Cody Cleveland
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Lucas Booth
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Taylor Bensel
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Daniel Minahan
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Haley M Hurowitz
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Tammy Tai
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Johanna Daily
- Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY 10461, USA
| | - Boris Nikolic
- Biomatics Capital, 1107 1st Avenue, Apartment 1305, Seattle, WA 98101, USA
| | - Lowell Wood
- Institute for Disease Modeling, Bellevue, WA 98005, USA
| | | | - Robert Langer
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. .,Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Giovanni Traverso
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. .,Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.,Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| |
Collapse
|
25
|
Seth A, Lafargue D, Poirier C, Badier T, Delory N, Laporte A, Delbos JM, Jeannin V, Péan JM, Ménager C. Optimization of magnetic retention in the gastrointestinal tract: Enhanced bioavailability of poorly permeable drug. Eur J Pharm Sci 2017; 100:25-35. [DOI: 10.1016/j.ejps.2016.12.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 12/08/2016] [Accepted: 12/20/2016] [Indexed: 11/30/2022]
|
26
|
Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: A recent update. Asian J Pharm Sci 2016. [DOI: 10.1016/j.ajps.2016.04.007] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
27
|
Kindgen S, Rach R, Nawroth T, Abrahamsson B, Langguth P. A Novel Disintegration Tester for Solid Dosage Forms Enabling Adjustable Hydrodynamics. J Pharm Sci 2016; 105:2402-9. [DOI: 10.1016/j.xphs.2016.05.028] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 04/26/2016] [Accepted: 05/25/2016] [Indexed: 10/21/2022]
|
28
|
Walsh PL, Bothe JR, Bhardwaj S, Hu M, Nofsinger R, Xia B, Persak S, Pennington J, Bak A. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets. Drug Dev Ind Pharm 2015; 42:836-44. [DOI: 10.3109/03639045.2015.1082583] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Paul L. Walsh
- Department of Analytical Sciences, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Rahway, NJ, USA,
| | - Jameson R. Bothe
- Department of Analytical Sciences, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Rahway, NJ, USA,
| | - Sunny Bhardwaj
- Department of Discovery Pharmaceutical Sciences, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Kenilworth, NJ, USA,
| | - Mengwei Hu
- Department of Discovery Pharmaceutical Sciences, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Kenilworth, NJ, USA,
| | - Rebecca Nofsinger
- Department of Biopharmaceutics, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, West Point, PA, USA, and
| | - Binfeng Xia
- Department of Biopharmaceutics, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, West Point, PA, USA, and
| | - Steven Persak
- Department of Device Development, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Rahway, NJ, USA
| | - Justin Pennington
- Department of Analytical Sciences, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Rahway, NJ, USA,
| | - Annette Bak
- Department of Discovery Pharmaceutical Sciences, Pharmaceutical Sciences & Clinical Supplies, Merck Research Laboratories, Kenilworth, NJ, USA,
| |
Collapse
|
29
|
Bose A, Harjoh N, Pal TK, Dan S, Wong TW. Drug release, preclinical and clinical pharmacokinetics relationships of alginate pellets prepared by melt technology. Expert Opin Drug Deliv 2015; 13:143-54. [PMID: 26307229 DOI: 10.1517/17425247.2015.1080686] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Alginate pellets prepared by the aqueous agglomeration technique experience fast drug dissolution due to the porous pre-formed calcium alginate microstructure. OBJECTIVE This study investigated in vitro drug release, preclinical and clinical pharmacokinetics relationships of intestinal-specific calcium acetate-alginate pellets against calcium-free and calcium carbonate-alginate pellets. METHOD Alginate pellets were prepared by solvent-free melt pelletization instead of aqueous agglomeration technique using chlorpheniramine maleate as model drug. RESULTS A fast in situ calcium acetate dissolution in pellets resulted in rapid pellet breakup, soluble Ca(2+) crosslinking of alginate fragments and drug dissolution retardation at pH 1.2, which were not found in other pellet types. The preclinical drug absorption rate was lower with calcium acetate loaded than calcium-free alginate pellets. In human subjects, however, the extent and the rate of drug absorption were higher from calcium acetate-loaded pellets than calcium-free alginate pellets. The fine, dispersible and weakly gastric mucoadhesive calcium alginate pellets underwent fast human gastrointestinal transit. They released the drug at a greater rate than calcium-free pellets in the intestine, thereby promoting drug bioavailability. CONCLUSION Calcium acetate was required as a disintegrant more than as a crosslinking agent clinically to promote pellet fragmentation, fast gastrointestinal transit and drug release in intestinal medium, and intestinal-specific drug bioavailability.
Collapse
Affiliation(s)
- Anirbandeep Bose
- a 1 Universiti Teknologi MARA , Non-Destructive Biomedical and Pharmaceutical Research Centre, iPROMISE , Puncak Alam 42300, Malaysia.,b 2 Universiti Teknologi MARA, Particle Design Research Group, Faculty of Pharmacy , Puncak Alam, 42300, Selangor, Malaysia .,c 3 Acharya and Bm Reddy College of Pharmacy , Bangalore 107, India
| | - Nurulaini Harjoh
- a 1 Universiti Teknologi MARA , Non-Destructive Biomedical and Pharmaceutical Research Centre, iPROMISE , Puncak Alam 42300, Malaysia.,b 2 Universiti Teknologi MARA, Particle Design Research Group, Faculty of Pharmacy , Puncak Alam, 42300, Selangor, Malaysia
| | - Tapan Kumar Pal
- d 4 Jadavpur University, Bioequivalence Study Centre, Department of Pharmaceutical Technology , 713103, Kolkata, India
| | - Shubhasis Dan
- d 4 Jadavpur University, Bioequivalence Study Centre, Department of Pharmaceutical Technology , 713103, Kolkata, India
| | - Tin Wui Wong
- a 1 Universiti Teknologi MARA , Non-Destructive Biomedical and Pharmaceutical Research Centre, iPROMISE , Puncak Alam 42300, Malaysia.,b 2 Universiti Teknologi MARA, Particle Design Research Group, Faculty of Pharmacy , Puncak Alam, 42300, Selangor, Malaysia .,e 5 Universiti Teknologi MARA, CoRe Pharmaceutical and Life Sciences , Shah Alam, 40450, Selangor, Malaysia
| |
Collapse
|
30
|
Kindgen S, Wachtel H, Abrahamsson B, Langguth P. Computational Fluid Dynamics Simulation of Hydrodynamics and Stresses in the PhEur/USP Disintegration Tester Under Fed and Fasted Fluid Characteristics. J Pharm Sci 2015; 104:2956-68. [PMID: 26017815 DOI: 10.1002/jps.24511] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 04/12/2015] [Accepted: 05/04/2015] [Indexed: 11/09/2022]
Abstract
Disintegration of oral solid dosage forms is a prerequisite for drug dissolution and absorption and is to a large extent dependent on the pressures and hydrodynamic conditions in the solution that the dosage form is exposed to. In this work, the hydrodynamics in the PhEur/USP disintegration tester were investigated using computational fluid dynamics (CFD). Particle image velocimetry was used to validate the CFD predictions. The CFD simulations were performed with different Newtonian and non-Newtonian fluids, representing fasted and fed states. The results indicate that the current design and operating conditions of the disintegration test device, given by the pharmacopoeias, are not reproducing the in vivo situation. This holds true for the hydrodynamics in the disintegration tester that generates Reynolds numbers dissimilar to the reported in vivo situation. Also, when using homogenized US FDA meal, representing the fed state, too high viscosities and relative pressures are generated. The forces acting on the dosage form are too small for all fluids compared to the in vivo situation. The lack of peristaltic contractions, which generate hydrodynamics and shear stress in vivo, might be the major drawback of the compendial device resulting in the observed differences between predicted and in vivo measured hydrodynamics.
Collapse
Affiliation(s)
- Sarah Kindgen
- Department of Pharmaceutical Technology and Biopharmaceutics, Johannes Gutenberg University Mainz, Mainz, 55128, Germany
| | - Herbert Wachtel
- Boehringer Ingelheim Pharma GmbH and Company KG, Ingelheim, 55216, Germany
| | | | - Peter Langguth
- Department of Pharmaceutical Technology and Biopharmaceutics, Johannes Gutenberg University Mainz, Mainz, 55128, Germany
| |
Collapse
|
31
|
Seth A, Lafargue D, Poirier C, Péan JM, Ménager C. Performance of magnetic chitosan–alginate core–shell beads for increasing the bioavailability of a low permeable drug. Eur J Pharm Biopharm 2014; 88:374-81. [DOI: 10.1016/j.ejpb.2014.05.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 04/22/2014] [Accepted: 05/16/2014] [Indexed: 10/25/2022]
|
32
|
Bornhorst GM, Paul Singh R. Gastric Digestion In Vivo and In Vitro: How the Structural Aspects of Food Influence the Digestion Process. Annu Rev Food Sci Technol 2014; 5:111-32. [DOI: 10.1146/annurev-food-030713-092346] [Citation(s) in RCA: 121] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Gail M. Bornhorst
- Department of Biological and Agricultural Engineering, University of California, Davis, California 95616; ,
| | - R. Paul Singh
- Department of Biological and Agricultural Engineering, University of California, Davis, California 95616; ,
- Riddet Institute, Massey University, Palmerston North 4442, New Zealand
| |
Collapse
|
33
|
Lalloo AK, McConnell EL, Jin L, Elkes R, Seiler C, Wu Y. Decoupling the role of image size and calorie intake on gastric retention of swelling-based gastric retentive formulations: Pre-screening in the dog model. Int J Pharm 2012; 431:90-100. [DOI: 10.1016/j.ijpharm.2012.04.044] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Accepted: 04/16/2012] [Indexed: 10/28/2022]
|
34
|
Abstract
Abstract
Objectives
The in-vivo performance of oral modified-release dosage forms is determined by the interplay of various physiological- and dosage-form-derived parameters. Thus it is often a challenge to predict the in-vivo drug-release behaviour from modified-release dosage forms based solely on in-vitro release rates.
Key findings
For a long time the most common procedure to obtain in-vitro/in-vivo correlations for modified-release formulations was to apply test conditions typically used for quality control on a retrospective basis. Such so-called ‘compendial approaches’ are typically not biorelevant with respect to volumes, composition and physicochemical properties of the test media and also do not take into consideration the mechanical and hydrodynamic forces that may influence dosage-form behaviour during passage through the gastrointestinal tract.
Summary
This review provides an overview of physiological conditions relevant to in-vivo drug release and of dissolution models which, based on current scientific findings on human gastrointestinal physiology, have been developed to enable a better prediction of the in-vivo performance of oral MR dosage forms.
Collapse
Affiliation(s)
- Grzegorz Garbacz
- Institute of Pharmacy, Ernst Moritz Arndt University, Greifswald, Germany
| | - Sandra Klein
- Institute of Pharmacy, Ernst Moritz Arndt University, Greifswald, Germany
| |
Collapse
|
35
|
Weitschies W, Wilson CG. In vivo imaging of drug delivery systems in the gastrointestinal tract. Int J Pharm 2011; 417:216-26. [DOI: 10.1016/j.ijpharm.2011.07.031] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2011] [Revised: 07/19/2011] [Accepted: 07/19/2011] [Indexed: 11/17/2022]
|
36
|
Abstract
Numerous therapeutics demonstrate optimal absorption or activity at specific sites in the gastrointestinal (GI) tract. Yet, safe, effective pill retention within a desired region of the GI remains an elusive goal. We report a safe, effective method for localizing magnetic pills. To ensure safety and efficacy, we monitor and regulate attractive forces between a magnetic pill and an external magnet, while visualizing internal dose motion in real time using biplanar videofluoroscopy. Real-time monitoring yields direct visual confirmation of localization completely noninvasively, providing a platform for investigating the therapeutic benefits imparted by localized oral delivery of new and existing drugs. Additionally, we report the in vitro measurements and calculations that enabled prediction of successful magnetic localization in the rat small intestines for 12 h. The designed system for predicting and achieving successful magnetic localization can readily be applied to any area of the GI tract within any species, including humans. The described system represents a significant step forward in the ability to localize magnetic pills safely and effectively anywhere within the GI tract. What our magnetic pill localization strategy adds to the state of the art, if used as an oral drug delivery system, is the ability to monitor the force exerted by the pill on the tissue and to locate the magnetic pill within the test subject all in real time. This advance ensures both safety and efficacy of magnetic localization during the potential oral administration of any magnetic pill-based delivery system.
Collapse
|
37
|
Garbacz G, Klein S, Weitschies W. A biorelevant dissolution stress test device – background and experiences. Expert Opin Drug Deliv 2010; 7:1251-61. [DOI: 10.1517/17425247.2010.527943] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
38
|
Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010; 7:1388-405. [PMID: 20822152 DOI: 10.1021/mp100149j] [Citation(s) in RCA: 305] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Pharmaceutical solid oral dosage forms must undergo dissolution in the intestinal fluids of the gastrointestinal tract before they can be absorbed and reach the systemic circulation. Therefore, dissolution is a critical part of the drug-delivery process. The rate and extent of drug dissolution and absorption depend on the characteristics of the active ingredient as well as properties of the dosage form. Just as importantly, characteristics of the physiological environment such as buffer species, pH, bile salts, gastric emptying rate, intestinal motility, and hydrodynamics can significantly impact dissolution and absorption. While significant progress has been made since 1970 when the first compendial dissolution test was introduced (USP apparatus 1), current dissolution testing does not take full advantage of the extensive physiologic information that is available. For quality control purposes, where the question is one of lot-to-lot consistency in performance, using nonphysiologic test conditions that match drug and dosage form properties with practical dissolution media and apparatus may be appropriate. However, where in vitro-in vivo correlations are desired, it is logical to consider and utilize knowledge of the in vivo condition. This publication critically reviews the literature that is relevant to oral human drug delivery. Physiologically relevant information must serve as a basis for the design of dissolution test methods and systems that are more representative of the human condition. As in vitro methods advance in their physiological relevance, better in vitro-in vivo correlations will be possible. This will, in turn, lead to in vitro systems that can be utilized to more effectively design dosage forms that have improved and more consistent oral bioperformance.
Collapse
Affiliation(s)
- Deanna M Mudie
- College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, USA
| | | | | |
Collapse
|